Image

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Study on Investigational Treatment Involving Immune Cells and IL-15 in Advanced Solid Tumors

Recruiting
All
Phase 1/2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates advanced solid tumors. It evaluates the use of allogeneic NK cells supported by low-dose IL-15, with or without pembrolizumab.

The study evaluates the safety, tolerability, and potential anti-tumor effects of the investigational treatment. It focuses on determining an appropriate dose and observing any clinical activity.

  • Who can participate: Adults aged 18 and older with advanced solid tumors that have not responded to standard treatments can participate.
  • Study details: Participants will receive investigational immune cells after chemotherapy to support the cells' growth and longevity. Some may also receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
  • Study timelines: Participants are followed for at least 12 months.
Print
Study details
    Cancer
    Sarcoma
    Leukaemia
    Breast Cancer (Locally Advanced or Metastatic)
    Lung Cancer (Diagnosis)
    Colorectal Cancer
    Melanoma (Skin Cancer)
    Bladder Cancer
    Kidney Cancer
    Pancreatic Cancer Metastatic
    Liver Cancer (Primary and Metastatic)
    Ovarian Cancer
    Esophageal Cancer
    Glioblastoma
    Non-Melanoma Skin Cancer

NCT07410676

Essen Biotech

31 July 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.